Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Thursday

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect the company to post earnings of ($0.15) per share and revenue of $0.12 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 23, 2026 at 4:00 PM ET.

Alpha Tau Medical Stock Down 10.5%

DRTS opened at $11.97 on Tuesday. The firm’s 50 day simple moving average is $14.00 and its two-hundred day simple moving average is $10.94. The company has a market capitalization of $1.08 billion, a PE ratio of -11.51 and a beta of 1.28. Alpha Tau Medical has a 1-year low of $3.43 and a 1-year high of $15.79. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15.

Analyst Upgrades and Downgrades

DRTS has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Alpha Tau Medical in a report on Tuesday, October 20th. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, November 9th. Finally, Barclays upped their price target on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.20.

Check Out Our Latest Stock Analysis on DRTS

Insider Buying and Selling at Alpha Tau Medical

In other news, CFO Raphi Levy sold 2,871 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at $1,352,700. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is currently owned by insiders.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

Read More

Earnings History for Alpha Tau Medical (NASDAQ:DRTS)

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.